Xu lab: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
Peisheng Xu (talk | contribs) No edit summary |
Peisheng Xu (talk | contribs) |
||
(41 intermediate revisions by the same user not shown) | |||
Line 6: | Line 6: | ||
<font face="trebuchet ms" style="color:#000" size="4"> '''Welcome to Xu lab!''' </font> | <font face="trebuchet ms" style="color:#000" size="4"> '''Welcome to Xu lab!''' </font> | ||
'''Graduate Research Assistant and Postdoctoral Research Associate positions are available for highly self-motivated student. Please contact Dr. Xu ('''xup@ | '''Graduate Research Assistant and Postdoctoral Research Associate positions are available for highly self-motivated student. Please contact Dr. Xu ('''xup@cop.sc.edu''') for detailed information. | ||
== News== | |||
* '''Mingming''' and '''Xiangxiang''' received their Ph.D. degrees in the Summer of 2023. '''Congratulations Dr. Wang and Dr. Hu!''' (08/15/2023) | |||
*"'''Polymer/copper nanocomplex-induced lysosomal cell death promotes tumor lymphocyte infiltration and synergizes anti-PD-L1 immunotherapy for triple-negative breast cancer'''" by Xiangxiang, Mingming, and Shanshan is accepted for publication in ''Biomaterials Science''. (06/22/2023) | |||
* '''Mingming''' was named as '''Outstanding Graduate Student of the Year''' of College of Pharmacy. Congratulations! (03/24/2023) | |||
*"'''Strategies to overcome/penetrate the BBB for systemic nanoparticle delivery to the brain/brain tumor'''" by Haijun is accepted for publication in ''Advanced Drug Delivery Reviews''. (11/6/2022) | |||
*Our patent application, '''The fabrication and application of Hetero-Targeted Nano-Cocktail with Traceless Linkers''', has been approved by the US Patent and Trademark Office. The issued patent number is 11,478,493. (10/25/2022). | |||
*'''Xiaolong Huang''' from Nankai University, China, joins the lab on August 5th, 2022 as a graduate student. Welcome! | |||
*"'''A therapeutic sheep in metastatic wolf’s clothing: Trojan horse approach for cancer brain metastases treatment'''" by Haijun, Mingming, Shanshan, and Xiangxiang is accepted for publication in ''Nano-Micro Letters''. (04/4/2022) | |||
*"'''Esterase-activatable and GSH-responsive Triptolide Nano-prodrug for the Eradication of Pancreatic Cancer'''" by Binglin, Chen, Shanshan, and Mingming is accepted for publication in ''Advanced NanoBiomed Research''. (06/14/2021) | |||
*Our patent application, '''Preparations of Gold/Mesoporous Silica Hybrid Nanoparticle and Applications''', has been approved by the US Patent and Trademark Office. The issued patent number is 11,007,207. (05/18/2021). | |||
*Our patent application, '''The Fabrication of a Suramin-Loaded Nanoparticle and Its Application''', has been approved by the US Patent and Trademark Office. The issued patent number is 11,000,482. (05/11/2021) | |||
*"'''Nanogel-facilitated Protein Intracellular Specific Degradation through Trim-Away'''" by Binglin and Mingming is accepted for publication in ''Advanced Functional Materials''. (05/6/2021) | |||
*"'''Biomimetic Nanomedicine Coupled with Neoadjuvant Chemotherapy to Suppress Breast Cancer Metastasis via Tumor Microenvironment Remodeling'''" by Haijun, Mingming, Shanshan, and Xiangxiang is accepted for publication in ''Advanced Functional Materials''. (03/1/2021) | |||
*Our patent application, '''Nanoparticles for Brain Targeted Drug Delivery''', has been approved by the US Patent and Trademark Office. The issued patent number is 10,842,755. (11/24/2020) | |||
*Our patent application, '''Preparations of Poly(lactic-co-glycolic acid)/Polydopamine Core/Shell Hybrid Nanoparticle for Photothermal Applications''', has been approved by the US Patent and Trademark Office. The issued patent number is 10,835,605. (11/17/2020) | |||
*"'''Redox-Sensitive Nanocomplex for Targeted Delivery of Melittin '''" by Bei is accepted for publication in ''Toxins''. (09/10/2020) | |||
*"'''Carrier-free nano-assembly of curcumin-erlotinib conjugate for cancer targeted therapy'''" by Chen is accepted for publication in ''Advanced Healthcare Materials''. (08/18/2020) | |||
*"'''Enhanced photothermal therapy through the in-situ activation of a temperature and redox dual-sensitive nano-reservoir of triptolide'''" by Haijun is accepted for publication in ''Small''. (07/05/2020) | |||
*"'''Bioactivatable Self-quenched Nanogel for Targeted Photodynamic Therapy'''" by Huacheng is accepted for publication in ''Biomaterials Science''. (09/18/2019) | |||
*"'''Hetero-targeted nano-cocktail with traceless linkers for eradicating cancer'''" by Binglin, Chen, Mingming, and Eli is accepted for publication in ''Advanced Functional Materials''. (08/29/2019) | |||
*"'''Pyridyl Disulfide Functionalized Polymers as Nanotherapeutic Platforms'''" by Binglin and Chen is accepted for publication in ''Advanced Therapeutics''. (05/30/2019) | |||
*"'''Smart Mesoporous Silica Nanoparticles for Protein Delivery'''" by Haijun is accepted for publication in ''Nanomaterials''. (03/23/2019) | |||
*'''Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan based nanoparticles''' by Bei is accepted for publication in ''Acta Biomaterialia''. (12/04/2018) | |||
*Dr. Xu visited and delivered an invited talk at Shanghai University of Traditional Chinese Medicine, Shanghai, China (06/29/2018) | |||
*Dr. Xu visited and delivered an invited talk at Zhejiang Univeristy, Hangzhou, China (06/27/2018) | |||
*"'''miR-489 regulates autophagy, cell viability and chemo-resistance in breast cancer cells'''" , a study collaborated with Dr. Hexin Chen that Eleni and Peisheng participated in as co-authors, is accepted for publication in ''Molecular Cancer Research '' (05/01/2018) | |||
*Our patent application, '''Polymeric Prodrug of Disulfiram and Application Thereof''', has been approved by the US Patent and Trademark Office. The issued patent number is 9,861,704. (01/09/2018) | |||
*"'''Repurposing Disulfiram for Cancer Therapy via Targeted Nanotechnology through Enhanced Tumor Mass Penetration and Disassembly'''" by Huacheng, Eleni, and Jing is accepted for publication in ''Acta Biomaterialia''. (12/18/2017) | |||
*Our patent application, '''POLYMER/COPPER COMBINATION FOR TARGETED CANCER THERAPY''', has been approved by the US Patent and Trademark Office. The issued patent number is 9,822,202. (11/01/2017) | |||
* Our research in '''Alzheimer's Disease''' is reported on '''WCBD TV''' [http://counton2.com/2017/05/01/local-advocates-fight-against-progressive-disease/] | |||
Line 164: | Line 251: | ||
==Personnel== | ==Personnel== | ||
*'''Xiaoyu Feng''' from Nanjing University of Chinese Medicine, China, joins the lab on December 20th, 2023 as a graduate student. Welcome! | |||
*'''Dr. Haijun Liu''' from Shanghai Jiao Tong University, joins the lab on September 21th, 2018 as a post-doctoral associate. Welcome aboard! | |||
*'''Mingming Wang''' from Zhengzhou University, China, joins the lab on August 9th, 2018 as a graduate student. Welcome! | |||
*'''Xiangxiang Hu''' from Fudan University, China, joins the lab on August 9th, 2018 as a graduate student. Welcome! | |||
*'''Dr. Chen Cheng''' from Nankai University, joins the lab on March 20, 2018 as a post-doctoral associate. Welcome aboard! | |||
*'''Dr. Binglin Sui''' from the University of Central Florida, joins the lab on January 2nd, 2018 as a post-doctoral associate. Welcome aboard! | |||
*'''Dr. Renjith P. Johnson ''' from Pusan National University, Korea, joins the lab on May 4th, 2015 as a post-doctoral associate. Welcome aboard! | *'''Dr. Renjith P. Johnson ''' from Pusan National University, Korea, joins the lab on May 4th, 2015 as a post-doctoral associate. Welcome aboard! | ||
Line 205: | Line 310: | ||
'''Peisheng Xu''', Ph.D. | '''Peisheng Xu''', Ph.D. | ||
Professor of Pharmaceutics | |||
[https://www | [https://www.sc.edu/study/colleges_schools/pharmacy/faculty-staff/xu_peisheng.php Department of Drug Discovery and Biomedical Sciences] | ||
College of Pharmacy | |||
[http://www.sc.edu/ University of South Carolina] | [http://www.sc.edu/ University of South Carolina] | ||
Line 215: | Line 320: | ||
715 Sumter St, | 715 Sumter St, 609D | ||
Columbia, SC | Columbia, SC 29208 | ||
Phone: 803-777-0075 | Phone: 803-777-0075 | ||
Line 223: | Line 328: | ||
Fax: 803-777-8356 | Fax: 803-777-8356 | ||
xup@ | xup@cop.sc.edu |
Latest revision as of 13:36, 9 December 2023
Home ; Research ; Lab Members ; Publications ; Contact ; Internal ; Talks ;
Welcome to Xu lab! Graduate Research Assistant and Postdoctoral Research Associate positions are available for highly self-motivated student. Please contact Dr. Xu (xup@cop.sc.edu) for detailed information.
News
Personnel
Contact information:Peisheng Xu, Ph.D. Professor of Pharmaceutics Department of Drug Discovery and Biomedical Sciences College of Pharmacy
715 Sumter St, 609D Columbia, SC 29208 Phone: 803-777-0075 Fax: 803-777-8356 xup@cop.sc.edu |